{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T09:09:57Z","timestamp":1788685797595,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biochem Genet"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10528-026-11408-z","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T04:33:12Z","timestamp":1780893192000},"page":"7587-7607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epirubicin-Induced Upregulation of miR-143-3p and miR-145 Enhances Cytotoxicity in MCF-7, MDA-MB-231, and BT-474 Breast Cancer Cell Lines"],"prefix":"10.1007","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9669-7397","authenticated-orcid":false,"given":"Morteza","family":"Rajabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6664-4798","authenticated-orcid":false,"given":"Niki Ghambari","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1083-8627","authenticated-orcid":false,"given":"Mahsa","family":"Mombeyni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-6672","authenticated-orcid":false,"given":"Roudabeh Behzadi","family":"Andouhjerdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"11408_CR1","first-page":"125","volume":"19","author":"N Ahmadiankia","year":"2016","unstructured":"Ahmadiankia N, Moghaddam HK, Mishan MA, Bahrami AR, Naderi-Meshkin H, Bidkhori HR, Moghaddam M, Mirfeyzi SJ (2016) Berberine suppresses migration of MCF-7 breast cancer cells through down-regulation of chemokine receptors. Iran J Basic Med Sci 19:125\u2013131","journal-title":"Iran J Basic Med Sci"},{"key":"11408_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15041222","author":"R Ansaar","year":"2023","unstructured":"Ansaar R, Meech R, Rowland A (2023) A physiologically based pharmacokinetic model to predict determinants of variability in Epirubicin exposure and tissue distribution. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15041222","journal-title":"Pharmaceutics"},{"key":"11408_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2023.154792","author":"V Asghariazar","year":"2023","unstructured":"Asghariazar V, Kadkhodayi M, Sarailoo M, Jolfayi AG, Baradaran B (2023) MicroRNA-143 as a potential tumor suppressor in cancer: an insight into molecular targets and signaling pathways. Pathology. https:\/\/doi.org\/10.1016\/j.prp.2023.154792","journal-title":"Pathology"},{"key":"11408_CR4","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1080\/1120009X.2020.1740389","volume":"32","author":"E Cacan","year":"2020","unstructured":"Cacan E, Ozmen ZC (2020) Regulation of Fas in response to bortezomib and epirubicin in colorectal cancer cells. J Chemother 32:193\u2013201","journal-title":"J Chemother"},{"key":"11408_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jff.2020.104130","volume":"73","author":"W-J Cheng","year":"2020","unstructured":"Cheng W-J, Zhang P-P, Luo Q-Q, Deng S-M, Jia A-Q (2020) The chemosensitizer ferulic acid enhances epirubicin-induced apoptosis in MDA-MB-231 cells. J Funct Foods 73:104130","journal-title":"J Funct Foods"},{"key":"11408_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13133789","volume":"13","author":"S Chiujdea","year":"2024","unstructured":"Chiujdea S, Ferro M, Vartolomei MD, Lucarelli G, Bekku K, matsukawa A, Parizi MK, Klemm J, Tsuboi I, Fazekas T, Mancon S, Shariat SF (2024) Epirubicin and non-muscle invasive bladder cancer treatment: A systematic review. J Clin Med 13:3789","journal-title":"J Clin Med"},{"key":"11408_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241210022","volume":"24","author":"WC Cho","year":"2023","unstructured":"Cho WC, Wong CF, Li KP, Fong AH, Fung KY, Au JS (2023) miR-145 as a potential biomarker and therapeutic target in patients with non-small cell lung cancer. Int J Mol Sci 24:10022","journal-title":"Int J Mol Sci"},{"key":"11408_CR8","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1016\/j.ajpath.2017.08.002","volume":"187","author":"WB Coleman","year":"2017","unstructured":"Coleman WB, Anders CK (2017) Discerning Clinical Responses in Breast Cancer Based On Molecular Signatures. Am J Pathol 187:2199\u20132207","journal-title":"Am J Pathol"},{"key":"11408_CR9","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1186\/s12889-025-24036-w","volume":"25","author":"ZG Dessie","year":"2025","unstructured":"Dessie ZG, Zewotir T (2025) Global determinants of breast cancer mortality: a comprehensive meta-analysis of clinical, demographic, and lifestyle risk factors. BMC Public Health 25:2640","journal-title":"BMC Public Health"},{"key":"11408_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1586\/14737140.4.2.189","volume":"4","author":"H Earl","year":"2004","unstructured":"Earl H, Iddawela M (2004) Epirubicin as adjuvant therapy in breast cancer. Expert Rev Anticancer Ther 4:189\u2013195","journal-title":"Expert Rev Anticancer Ther"},{"key":"11408_CR11","first-page":"217","volume":"80","author":"T Eslammanesh","year":"2025","unstructured":"Eslammanesh T, Mirshekari A, Dahmardeh N, Ghafari M, Mahmoodi F, Jahantigh M, Mirzaei AR, Fazeli-Nasab B (2025) Mechanisms of miRNAs and their expression in gastric cancer. Arch Razi Inst 80:217\u2013224","journal-title":"Arch Razi Inst"},{"key":"11408_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232012074","author":"AR Estrada-Perez","year":"2022","unstructured":"Estrada-Perez AR, Bakalara N, Garcia-Vazquez JB, Rosales-Hernandez MC, Fernandez-Pomares C, Correa-Basurto J (2022) LC-MS based lipidomics depict Phosphatidylethanolamine as biomarkers of TNBC MDA-MB-231 over nTNBC MCF-7 cells. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms232012074","journal-title":"Int J Mol Sci"},{"key":"11408_CR13","doi-asserted-by":"publisher","first-page":"59714","DOI":"10.18632\/oncotarget.10845","volume":"7","author":"M Gao","year":"2016","unstructured":"Gao M, Miao L, Liu M, Li C, Yu C, Yan H, Yin Y, Wang Y, Qi X, Ren J (2016) miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Oncotarget 7:59714\u201359726","journal-title":"Oncotarget"},{"key":"11408_CR14","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1111\/cas.13059","volume":"107","author":"W Guo","year":"2016","unstructured":"Guo W, Wang Y, Wang Z, Wang YP, Zheng H (2016) Inhibiting autophagy increases epirubicin\u2019s cytotoxicity in breast cancer cells. Cancer Sci 107:1610\u20131621","journal-title":"Cancer Sci"},{"key":"11408_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-27415-8","volume":"13","author":"S Hajibabaei","year":"2023","unstructured":"Hajibabaei S, Sotoodehnejadnematalahi F, Nafissi N, Zeinali S, Azizi M (2023) Aberrant promoter hypermethylation of miR-335 and miR-145 is involved in breast cancer PD-L1 overexpression. Sci Rep 13:1003","journal-title":"Sci Rep"},{"key":"11408_CR16","doi-asserted-by":"publisher","first-page":"9630","DOI":"10.48048\/tis.2025.9630","volume":"22","author":"SM Haryana","year":"2025","unstructured":"Haryana SM, Oktriani R, Faiha DK, Conara FC, Dafip M, Setiasari DW (2025) miR-143-3p: A Critical Regulator of KRAS and HRAS with Potential for Targeted Therapies in Breast Cancer. Trends Sci 22:9630\u20139630","journal-title":"Trends Sci"},{"key":"11408_CR17","doi-asserted-by":"publisher","first-page":"7065","DOI":"10.1158\/0008-5472.CAN-05-1783","volume":"65","author":"MV Iorio","year":"2005","unstructured":"Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Menard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65:7065\u20137070","journal-title":"Cancer Res"},{"key":"11408_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0186658","volume":"12","author":"C Johannessen","year":"2017","unstructured":"Johannessen C, Moi L, Kiselev Y, Pedersen MI, Dalen SM, Braaten T, Busund LT (2017) Expression and function of the miR-143\/145 cluster in vitro and in vivo in human breast cancer. PLoS One 12:e0186658","journal-title":"PLoS One"},{"key":"11408_CR19","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12964-023-01302-1","volume":"22","author":"SU Khan","year":"2024","unstructured":"Khan SU, Fatima K, Aisha S, Malik F (2024) Unveiling the mechanisms and challenges of cancer drug resistance. Cell Commun Signal 22:109","journal-title":"Cell Commun Signal"},{"key":"11408_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12081801","volume":"12","author":"M Koirala","year":"2024","unstructured":"Koirala M, Dipaola M (2024) Overcoming cancer resistance: strategies and modalities for effective treatment. Biomedicines 12:1801","journal-title":"Biomedicines"},{"issue":"Suppl 1","key":"11408_CR21","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.3816\/CBC.2000.s.012","volume":"1","author":"M Levine","year":"2000","unstructured":"Levine M (2000) Epirubicin in breast cancer: present and future. Clin Breast Cancer 1(Suppl 1):S62\u2013S67","journal-title":"Clin Breast Cancer"},{"key":"11408_CR22","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.cca.2021.08.007","volume":"522","author":"W Li","year":"2021","unstructured":"Li W, Zhang Z, Wang B, Liang N, Zhou Q, Long S (2021) MicroRNA and cyclooxygenase-2 in breast cancer. Clin Chim Acta 522:36\u201344","journal-title":"Clin Chim Acta"},{"key":"11408_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0197523","volume":"13","author":"ST Lim","year":"2018","unstructured":"Lim ST, Park CH, Kim SY, Nam SJ, Kang EY, Moon BI, Lee HJ, Jeon YW, Gwak H, Suh YJ (2018) The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer. PLoS One 13:e0197523","journal-title":"PLoS One"},{"key":"11408_CR24","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1002\/onco.13581","volume":"26","author":"B Lim","year":"2021","unstructured":"Lim B, Song J, Ibrahim NK, Koenig KB, Chavez-Macgregor M, Ensor JE JR., Gomez JS, Krishnamurthy S, Caudle AS, Shaitelman SF, Whitman GJ, Valero V (2021) A randomized phase II study of sequential Eribulin versus Paclitaxel followed by FAC\/FEC as neoadjuvant therapy in patients with operable HER2-Negative breast cancer. Oncologist 26:e230\u2013e240","journal-title":"Oncologist"},{"key":"11408_CR25","doi-asserted-by":"publisher","first-page":"61731","DOI":"10.18632\/oncotarget.18686","volume":"8","author":"S-Y Liu","year":"2017","unstructured":"Liu S-Y, Li X-Y, Chen W-Q, Hu H, Luo B, Shi Y-X, Wu T-W, Li Y, Kong Q-Z, Lu H-D (2017) Demethylation of the MIR145 promoter suppresses migration and invasion in breast cancer. Oncotarget 8:61731","journal-title":"Oncotarget"},{"key":"11408_CR26","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1080\/10408347.2021.2007469","volume":"53","author":"MT Luiz","year":"2023","unstructured":"Luiz MT, Dutra JAP, di Filippo LD, Junior AGT, Tofani LB, Marchetti JM, Chorilli M (2023) Epirubicin: Biological Properties, Analytical Methods, and Drug Delivery Nanosystems. Crit Rev Anal Chem 53:1080\u20131093","journal-title":"Crit Rev Anal Chem"},{"key":"11408_CR27","first-page":"317","volume":"69","author":"A Modarresi Chahardehi","year":"2020","unstructured":"Modarresi Chahardehi A, Arsad H, Ismail NZ, Lim V (2020) Low cytotoxicity, and antiproliferative activity on cancer cells, of the plant Senna alata (Fabaceae). Revista de Biolog\u00eda Trop 69:317\u2013330","journal-title":"Revista de Biolog\u00eda Trop"},{"key":"11408_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1385632","author":"A Modarresi Chahardehi","year":"2024","unstructured":"Modarresi Chahardehi A, Afrooghe A, Emtiazi N, Rafiei S, Rezaei NJ, Dahmardeh S, Farz F, Naderi Z, Arefnezhad R, Motedayyen H (2024) MicroRNAs and angiosarcoma: are there promising reports? Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2024.1385632","journal-title":"Front Oncol"},{"key":"11408_CR29","first-page":"1164","volume":"53","author":"P Mohammadi","year":"2024","unstructured":"Mohammadi P, Forouzesh F, Kouhkan F (2024) Short Chain Fatty Acid Sodium Butyrate Increases miR-21, miR-143 and miR-145 Expression in Human Colorectal Cancer HCT-116 Cell Line. Iran J Public Health 53:1164\u20131174","journal-title":"Iran J Public Health"},{"key":"11408_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0234012","volume":"15","author":"HR Moon","year":"2020","unstructured":"Moon HR, Ospina-Mu\u00f1oz N, Noe-Kim V, Yang Y, Elzey BD, Konieczny SF, Han B (2020) Subtype-specific characterization of breast cancer invasion using a microfluidic tumor platform. PLoS One 15:e0234012","journal-title":"PLoS One"},{"key":"11408_CR31","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3390\/cancers12030708","volume":"12","author":"V Poli","year":"2020","unstructured":"Poli V, Secl\u00ec L, Avalle L (2020) The Microrna-143\/145 Cluster in Tumors: A Matter of Where and When. Cancers 12:708","journal-title":"Cancers"},{"key":"11408_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.currproblcancer.2024.101062","volume":"48","author":"DT Quang","year":"2024","unstructured":"Quang DT, Luong Thi T, Nguyen Di K, Vu Thi Quynh C, Nguyen Thi Hoa H, Phan Ngoc Q (2024) Illuminating the breast cancer survival rates among Southeast Asian women: a systematic review and meta-analysis spanning four decades. Curr Probl Cancer 48:101062","journal-title":"Curr Probl Cancer"},{"key":"11408_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2019.115131","volume":"27","author":"S Raje","year":"2019","unstructured":"Raje S, Pandav K, Barthwal R (2019) Dual mode of binding of anti cancer drug epirubicin to G-quadruplex [d-(TTAGGGT)](4) containing human telomeric DNA sequence induces thermal stabilization. Bioorg Med Chem 27:115131","journal-title":"Bioorg Med Chem"},{"key":"11408_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115264","volume":"166","author":"M Roshani","year":"2023","unstructured":"Roshani M, Molavizadeh D, Sadeghi S, Jafari A, Dashti F, Mirazimi SMA, Ahmadi Asouri S, Rajabi A, Hamblin MR, Anoushirvani AA, Mirzaei H (2023) Emerging roles of miR-145 in gastrointestinal cancers: a new paradigm. Biomed Pharmacother 166:115264","journal-title":"Biomed Pharmacother"},{"key":"11408_CR35","doi-asserted-by":"publisher","first-page":"R115","DOI":"10.1530\/VB-20-0012","volume":"2","author":"D Sawant","year":"2020","unstructured":"Sawant D, Lilly B (2020) MicroRNA-145 targets in cancer and the cardiovascular system: evidence for common signaling pathways. Vasc Biol 2:R115\u2013R128","journal-title":"Vasc Biol"},{"key":"11408_CR36","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/cdd.2009.117","volume":"17","author":"R Spizzo","year":"2010","unstructured":"Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, Davuluri R, Croce CM, Mills G, Negrini M, Calin GA (2010a) miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. Cell Death Differ 17:246\u201354","journal-title":"Cell Death Differ"},{"key":"11408_CR37","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/cdd.2009.117","volume":"17","author":"R Spizzo","year":"2010","unstructured":"Spizzo R, Nicoloso MS, Lupini L, Lu Y, Fogarty J, Rossi S, Zagatti B, Fabbri M, Veronese A, Liu X, Davuluri R, Croce CM, Mills G, Negrini M, Calin GA (2010b) miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-\u03b1 in human breast cancer cells. Cell Death Differ 17:246\u2013254","journal-title":"Cell Death Differ"},{"key":"11408_CR38","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.gene.2016.09.016","volume":"594","author":"Z Sun","year":"2016","unstructured":"Sun Z, Wu Z, Zhang F, Guo Q, Li L, Li K, Chen H, Zhao J, Song D, Huang Q, Li L, Xiao J (2016) PRAME is critical for breast cancer growth and metastasis. Gene 594:160\u2013164","journal-title":"Gene"},{"key":"11408_CR39","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41598-017-18739-3","volume":"8","author":"X Sun","year":"2018","unstructured":"Sun X, Dai G, Yu L, Hu Q, Chen J, Guo W (2018) miR-143-3p inhibits the proliferation, migration and invasion in osteosarcoma by targeting FOSL2. Sci Rep 8:606","journal-title":"Sci Rep"},{"key":"11408_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecoenv.2020.110348","volume":"193","author":"PK Tsai","year":"2020","unstructured":"Tsai PK, Wu SW, Chiang CY, Lee MW, Chen HY, Chen WY, Chen CJ, Yang SF, Yeh CB, Kuan YH (2020) Evaluation of cytotoxicity, apoptosis, and genotoxicity induced by indium chloride in macrophages through mitochondrial dysfunction and reactive oxygen species generation. Ecotoxicol Environ Saf 193:110348","journal-title":"Ecotoxicol Environ Saf"},{"key":"11408_CR41","doi-asserted-by":"publisher","first-page":"28711","DOI":"10.18632\/oncotarget.15646","volume":"8","author":"F Wang","year":"2017","unstructured":"Wang F, Liu J, Zou Y, Jiao Y, Huang Y, Fan L, Li X, Yu H, He C, Wei W, Wang H, Sun G (2017) MicroRNA-143-3p, up-regulated in H. pylori-positive gastric cancer, suppresses tumor growth, migration and invasion by directly targeting AKT2. Oncotarget 8:28711\u201328724","journal-title":"Oncotarget"},{"key":"11408_CR42","doi-asserted-by":"publisher","first-page":"256","DOI":"10.14715\/cmb\/2021.67.5.35","volume":"67","author":"D Wang","year":"2022","unstructured":"Wang D, Wang C, Sun L, Lu X, Shi J, Chen J, Zhang X (2022) MiR-143-3p Increases the Radiosensitivity of Breast Cancer Cells Through FGF1. Cell Mol Biol (Noisy-le-grand) 67:256\u2013262","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"key":"11408_CR43","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/ncrna6030029","volume":"6","author":"JS Wong","year":"2020","unstructured":"Wong JS, Cheah YK (2020) Potential miRNAs for miRNA-Based Therapeutics in Breast Cancer. Non-Coding RNA 6:29","journal-title":"Non-Coding RNA"},{"key":"11408_CR44","doi-asserted-by":"publisher","DOI":"10.3892\/or.2024.8772","volume":"52","author":"J Wu","year":"2024","unstructured":"Wu J, Zhu Y, Liu D, Cong Q, Bai C (2024) Biological functions and potential mechanisms of miR\u2011143\u20113p in cancers. Oncol Rep 52:113","journal-title":"Oncol Rep"},{"key":"11408_CR45","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.biochi.2018.01.003","volume":"147","author":"C Xia","year":"2018","unstructured":"Xia C, Yang Y, Kong F, Kong Q, Shan C (2018) MiR-143-3p inhibits the proliferation, cell migration and invasion of human breast cancer cells by modulating the expression of MAPK7. Biochimie 147:98\u2013104","journal-title":"Biochimie"},{"key":"11408_CR46","first-page":"22764","volume":"9","author":"J Xiong","year":"2016","unstructured":"Xiong J, Fan F, Zhang Y, Chen W, Mao W (2016) Epirubicin inhibits proliferation of breast cancer cells through upregulating p21cip1 expression. Int J Clin Exp Med 9:22764\u201322772","journal-title":"Int J Clin Exp Med"},{"key":"11408_CR47","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1111\/cas.14517","volume":"111","author":"W Xu","year":"2020","unstructured":"Xu W, Hua Y, Deng F, Wang D, Wu Y, Zhang W, Tang J (2020) MiR-145 in cancer therapy resistance and sensitivity: A comprehensive review. Cancer Sci 111:3122\u20133131","journal-title":"Cancer Sci"},{"key":"11408_CR48","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/1476-4598-13-220","volume":"13","author":"X Yan","year":"2014","unstructured":"Yan X, Chen X, Liang H, Deng T, Chen W, Zhang S, Liu M, Gao X, Liu Y, Zhao C, Wang X, Wang N, Li J, Liu R, Zen K, Zhang CY, Liu B, Ba Y (2014) miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. Mol Cancer 13:220","journal-title":"Mol Cancer"},{"key":"11408_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12523-z","volume":"24","author":"W Yan","year":"2024","unstructured":"Yan W, Yang H, Duan D, Wu Y, Liu Y, Mao J, Zhao Y, Ye J (2024) Bone marrow mesenchymal stem cells-derived exosomal miR-145-5p reduced non-small cell lung cancer cell progression by targeting SOX9. BMC Cancer 24:883","journal-title":"BMC Cancer"},{"key":"11408_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70005","volume":"13","author":"MH Yang","year":"2024","unstructured":"Yang MH, Huang CS, Chang DY, Hu FC, Huang SM, Huang PH, Chen IC, Chen TW, Lin CH, Lu YS (2024) Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2-positive early breast cancer: a meta-regression analysis. Cancer Med 13:e70005","journal-title":"Cancer Med"},{"key":"11408_CR51","doi-asserted-by":"publisher","first-page":"969","DOI":"10.2147\/CMAR.S191696","volume":"11","author":"D Ye","year":"2019","unstructured":"Ye D, Shen Z, Zhou S (2019) Function of microRNA-145 and mechanisms underlying its role in malignant tumor diagnosis and treatment. Cancer Manag Res 11:969\u2013979","journal-title":"Cancer Manag Res"}],"container-title":["Biochemical Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10528-026-11408-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10528-026-11408-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10528-026-11408-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T08:11:06Z","timestamp":1788682266000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10528-026-11408-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["11408"],"URL":"https:\/\/doi.org\/10.1007\/s10528-026-11408-z","relation":{},"ISSN":["0006-2928","1573-4927"],"issn-type":[{"value":"0006-2928","type":"print"},{"value":"1573-4927","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study protocol was approved by the local ethics committee of Central Tehran Branch, Islamic Azad University, with the code: IR.IAU.CTB.REC.1403.074.","order":2,"name":"Ethics","label":"Ethical Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors consent to the publication of this article.","order":3,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}